Calcium Channel Blockers


Article Author:
Rita McKeever


Article Editor:
Richard Hamilton


Editors In Chief:
Sherri Murrell


Managing Editors:
Avais Raja
Orawan Chaigasame
Khalid Alsayouri
Kyle Blair
Radia Jamil
Erin Hughes
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Navid Mahabadi
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Abbey Smiley
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beenish Sohail
Hajira Basit
Phillip Hynes
Sandeep Sekhon


Updated:
9/30/2019 3:38:48 PM

Indications

In the 1970s, calcium channel antagonists, also known as calcium channel blockers, were widely used for many indications. This cardiovascular drug class is one of the leading causes of drug-related fatalities. They are often classified into 2 major categories, either non-dihydropyridines or dihydropyridines. The non-dihydropyridines include verapamil, a phenylalkylamine, and diltiazem, a benzothiazepine. The dihydropyridines include many other drugs, most of which end in "pine" (i.e., amlodipine and nicardipine).[1][2][3][4]

Cardiovascular indications include hypertension, coronary spasm, angina pectoris, supraventricular dysrhythmias, hypertrophic cardiomyopathy, and pulmonary hypertension. In addition to these, they are also prescribed for Raynaud’s phenomenon, subarachnoid hemorrhage, and migraine headaches.

Mechanism of Action

Calcium channel antagonists block the inward movement of calcium by binding to the L-type “long-acting” voltage-gated calcium channels in the heart, vascular smooth muscle, and pancreas. There are two major categories of calcium channel antagonists based on their primary physiologic effects. The non-dihydropyridines have inhibitory effects on the sinoatrial (SA), and atrioventricular (AV) nodes are resulting in a slowing of cardiac conduction and contractility. This allows for the treatment of hypertension, reduces oxygen demand, and helps to control the rate in tachydysrhythmias. The dihydropyridines, in therapeutic dosing, have a little direct effect on the myocardium, and instead are more often peripheral vasodilators which is why they are used for hypertension, post-intracranial hemorrhage associated vasospasm, and migraines.[5][6]

Absorption: Calcium channel antagonists are absorbed well orally, however many have low bioavailability due to hepatic first pass metabolism, primarily by CYP3A4.

Distribution: Calcium channel antagonists are highly protein bound, and many have high volumes of distribution.

Metabolism: In repeated doses, or in overdose, the hepatic enzymes responsible for metabolism become saturated and reduce first pass effects which therefore increases absorption of the active drug. Modified release formulations and saturation of metabolism of these drugs increase the half-life of various calcium channel antagonists.

Excretion: Calcium channel antagonists are primarily excreted renally after metabolism.

There is the potential for drug-drug interactions because calcium channel antagonists are metabolized by CYP3A4, which is responsible for the metabolism of many other xenobiotics.

Administration

Calcium channel antagonists can be administered intravenously or orally.

Adverse Effects

Non-dihydropyridines may cause constipation, worsening cardiac output, and bradycardia.

Dihydropyridines may lead to lightheadedness, flushing, headaches, and peripheral edema. The peripheral edema is likely related to the redistribution of fluid from the intravascular space to the interstitium.

Gingival hyperplasia has also been reported.

Contraindications

Non-dihydropyridines are contraindicated in those with heart failure with reduced ejection fraction, second or third-degree AV blockade, and sick sinus syndrome because of the possibility of causing bradycardia and worsening cardiac output.

Calcium channel antagonists are also contraindicated in patients with known hypersensitivity to the drug or its components. Other contraindications include sick sinus syndrome (except in patients with an artificial pacemaker), severe hypotension, acute myocardial infarction, and pulmonary congestion. Calcium channel antagonists may cause AV blockade or sinus bradycardia especially if taken with agents known to slow cardiac conduction. Dermatologic reactions and hypotension with or without syncope have been reported with calcium channel antagonist use. Peripheral edema may occur within 2 to 3 weeks of initiating calcium channel blocker therapy. Use with caution in renal and hepatic impairment. Consider initiating therapy at a lower dose.

Monitoring

Patients should be monitored closely. The improvement of their symptoms of angina or maintenance of their blood pressure is an indication of efficacy. A patient should be assessed regularly if these medications are being titrated quickly.[7][8][9]

Toxicity

Hypotension and bradycardia are the primary features seen in calcium channel antagonist poisoning. These findings are due to peripheral vasodilatation and reduced cardiac contractility.

Hypotension may be profound and life-threatening, it is caused by peripheral vasodilation, bradycardia, and decreased ionotropy.  The cardiac conduction may also be impaired with AV conduction abnormalities, complete heart block, and idioventricular rhythms.

Patients may present asymptomatic initially and progress rapidly to severe hypoperfusion and cardiovascular collapse. Symptoms may include lightheadedness, fatigue, change in mentation, syncope, coma, and sudden death. Non-cardiac symptoms may include nausea and vomiting, metabolic acidosis secondary to hypoperfusion, and hyperglycemia from the blockade of insulin release in the pancreas. The insulin blockade also impairs the uptake of glucose by myocardial cells which further contributes to the reduction of cardiac contractility and worsens hypotension. Severe poisoning can lead to pulmonary edema, presumably as a result of precapillary vasodilation and increased transcapillary pressure.

Dihydropyridines in mild to moderate overdose may cause reflex tachycardia; however, in severe overdose, there may be a loss of receptor selectivity leading to bradycardia.

Many factors may affect the severity of overdose including the calcium-channel antagonist dose, the formulation, ingestion with other cardioactive medications such as beta-blockers, the patient’s age, and comorbidities. These medications may also be life-threatening with as little as one tablet in small pediatric patients.

Hyperglycemia has been considered a prognostic indicator of the severity of calcium channel antagonist toxicity. Beta-islet cells in the pancreas depend on the influx of calcium through the L-type calcium channels to release insulin. In the case of calcium channel antagonist overdose, there is a reduction in the release of insulin and subsequent hyperglycemia.

As in any other overdose, it is important to maintain a patent airway. Obtain an electrocardiogram and place the patient on continuous monitoring including pulse oximetry. Obtain a chest x-ray and basic labs (including acetaminophen and salicylate levels if warranted). Initiate gastrointestinal (GI) decontamination early especially in the cases of large ingestions or those with sustained-release formulations in the appropriate settings (i.e., normal mental status, recent ingestion, among others.) Administer activated charcoal if the patient has presented early and is awake, alert, oriented, and protecting their airway. Whole bowel irrigation is an important option for those patients with massive overdoses or overdoses of sustained or extended release formulations which do not already have an ileus.

In the case of hypotension, initial treatment with intravenous fluids should be given with caution in those who have congestive heart failure, pulmonary edema, or kidney disease. Intravenous calcium administration may reverse the decreased cardiac contractility. Calcium chloride 10% (10 ml for 0.1 to 0.2 ml/kg) or calcium gluconate 10% (20 to 30 ml 0.3 to 0.4 ml/kg) may be administered intravenously and may be repeated every 5 to 10 minutes. Caution must be used with calcium chloride as it may cause skin necrosis when given through a peripheral line. Atropine is a reasonable initial treatment option, but it typically does not reverse the effects of calcium channel antagonist poisoning. Give glucagon as a bolus of 5 to 10 mg intravenously with caution for nausea and vomiting, and patients may be pre-medicated with antiemetics to help avoid this. If the patient is refractory to these interventions, initiate vasopressor therapy using intravenous norepinephrine or push-dose phenylephrine while preparing hyperinsulinemia/euglycemia (HIE) therapy. HIE increases cardiac contractility by enhancing the transport of glucose into the myocardial cells which corrects they hypo-insulinemia. Administer a bolus of insulin 1 unit/kg, followed by an infusion of 1 to 10 units/kg per hour. Monitor the patient’s glucose for hypoglycemia initially every 10 minutes and then every 30 to 60 minutes to maintain glucose between 100 to 200 mg/dL. Use a concomitant dextrose infusion to maintain these levels. If the initial glucose is less than 200 mg/dL, administer a bolus dose of glucose. Monitor glucose levels and potassium levels closely. Intravenous lipid emulsion therapy lacks clear evidence for efficacy but is a consideration if all else fails. Administer a bolus of intravenous lipid emulsion 20% 1.5 ml/kg, repeat if needed, and then start an infusion of 0.25 to 0.5 ml/kg per minute for an hour. Reports suggest that the use of methylene blue, especially in those with amlodipine overdose resulting in vasodilatory shock, may be effective. Phosphodiesterase inhibitors have also been used in calcium channel antagonist therapy. They increase cardiac output by inhibiting the breakdown of cAMP.  Extracorporeal membrane oxygenation (ECMO) has proven successful in cases refractory to all of the above interventions since it maintains perfusion to vital organs and continues hepatic metabolism.

Enhancing Healthcare Team Outcomes

Healthcare workers who prescribe calcium channel blockers should be familiar with their adverse effects. Both hypotension and bradycardia can occur in patients on calcium channel blockers and require immediate attention. Thus, patients on these agents need to be monitored as long as they remain on the drugs. If side effects do occur, the patient's treatment depends on symptoms. All symptomatic patients with hypotension or bradycardia should be asked to go to the emergency department. In asymptomatic patients, the drug should be withheld and dosage changes or an alternative medication may be required. In an ICU setting, nurses should know how to manage hypotension and bradycardia.


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Calcium Channel Blockers - Questions

Take a quiz of the questions on this article.

Take Quiz
Which of the following antihypertensive drugs is known to cause salt and water retention, particularly pedal edema?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of following class of medications most significantly potentiates the actions of a neuromuscular antagonist?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is a Class IV antiarrhythmic drug?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What of the following is not an effect of calcium channel blockers?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following course of actions is false in respect to patients with symptomatic valvular disease?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following drugs is a calcium channel blocker?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Calcium channel blockers result in an increase in which one of the following?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A patient presents to the emergency department following an overdose of her antihypertensive medications. She is noted to have profound bradycardia and hypotension. Which of the following statements is true when differentiating calcium channel blocker toxicity from beta-blocker toxicity?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Calcium Channel Blockers - References

References

Dabush-Elisha I,Goren O,Herscovici A,Matot I, Bradycardia During Laparoscopic Surgeries: A Retrospective Cohort Study. World journal of surgery. 2019 Feb 8;     [PubMed]
Chakraborty RK,Hamilton RJ, Calcium Channel Blocker Toxicity 2018 Jan;     [PubMed]
Kim J,Kim YA,Hwangbo B,Kim MJ,Cho H,Hwangbo Y,Lee ES, Effect of Antihypertensive Medications on Sepsis-Related Outcomes: A Population-Based Cohort Study. Critical care medicine. 2019 Jan 24;     [PubMed]
Liss B,Striessnig J, The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease. Annual review of pharmacology and toxicology. 2019 Jan 6;     [PubMed]
Lin Y,Ma L, Blood pressure lowering effect of calcium channel blockers on perioperative hypertension: A systematic review and meta-analysis. Medicine. 2018 Nov;     [PubMed]
Pavasini R,Camici PG,Crea F,Danchin N,Fox K,Manolis AJ,Marzilli M,Rosano GMC,Lopez-Sendon JL,Pinto F,Balla C,Ferrari R, Anti-anginal drugs: Systematic review and clinical implications. International journal of cardiology. 2018 Dec 4;     [PubMed]
Hernandorena I,Bailly H,Piccoli M,Beunardeau M,Cohen A,Hanon O, [Hypertension in the elderly]. Presse medicale (Paris, France : 1983). 2019 Jan 18;     [PubMed]
Jurić D,Pavličević I,Marušić A,Malički M,Buljan I,Šarotić V,Mrduljaš-Đujić N,Komparak A,Vujević M,De Micheli-Vitturi D,Šušnjar P,Puljiz T,Jerčić M,Leskur D,Marušić M, Effectiveness of treatment of newly diagnosed hypertension in family medicine practices in South Croatia. BMC family practice. 2019 Jan 14;     [PubMed]
Prosser HCG,Azzam O,Schlaich MP, Resistant Hypertension: Which Agent? Heart, lung     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Nurse-Elder Adult Care. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Nurse-Elder Adult Care, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Nurse-Elder Adult Care, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Nurse-Elder Adult Care. When it is time for the Nurse-Elder Adult Care board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Nurse-Elder Adult Care.